Beijing Qihengxing Biotechnology Co., Ltd. was established in 2018. It is a national high-tech enterprise with many invention patents. Relying on core technology platforms such as mutant library Taq enzyme development technology with independent intellectual property rights, large-scale magnetic bead preparation and diversified surface modification technology, and extremely low concentration nucleic acid sample preservation technology, the company has developed many high-quality products in four major application directions, including molecular biology, NGS applications, synthetic biology related, and diagnostic reagent CDMO, and has built a technology/practical training and product customization development service platform based on the integration of industry, academia and research. Some of the advantageous products are as follows:
Qihengxing Biotechnology has been committed to independent research and development and high-quality production since its inception. All the formal products currently supplied are produced in standardized production workshops that meet ISO13485/ISO9001 quality system certification, and a strict product traceability mechanism has been established to effectively ensure product stability.
Some partners (in no particular order)
